PCSA — Processa Pharmaceuticals, Inc.

Summary of Processa Pharmaceuticals Q4 2022 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2022, Processa had a cash balance of $6.5 million. Following a capital raise of $6.4 million in early 2023, the total cash available is $12.9 million, expected to fund operations through Q3 2024.
• Net Loss: The company reported a GAAP net loss of $27.4 million ($1.70 per share) for 2022, up from a loss of $11.4 million ($0.75 per share) in 2021. The increase was attributed to a $7.3 million non-cash impairment and higher clinical trial costs.
• R&D Expenses: Research and development costs rose to $11.5 million, an increase of $4.6 million from 2021. General and administrative expenses also increased to $8.8 million from $4.7 million, largely due to stock-based compensation.

2. Strategic Updates and Business Highlights

• Focus Shift: The company is narrowing its focus to three next-generation chemotherapy drugs, prioritizing oncology treatments over its previous five-drug portfolio.
• Drug Development: The next-generation drugs aim to improve efficacy and reduce side effects compared to existing chemotherapy options. Key drugs include next-generation versions of capecitabine, gemcitabine, and irinotecan.
• Regulatory Strategy: Processa is utilizing the FDA’s Project Optimus principles to enhance drug development efficiency and approval likelihood, which is expected to differentiate its products from competitors.

3. Forward Guidance and Outlook

• Clinical Trials: The company plans to meet with the FDA in mid-April 2023 to discuss the Phase 2b trial for next-generation capecitabine, with hopes to initiate the trial by late 2023 and complete enrollment by the end of 2024. Similar timelines are anticipated for next-generation gemcitabine and irinotecan.
• Partnerships: Processa is exploring licensing opportunities for its non-oncology drugs and may consider monetizing its next-generation chemotherapy drugs.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The significant increase in net loss raises concerns about the company’s financial health and sustainability, especially as a pre-revenue entity.
• Stock Performance: Management acknowledged the underperformance of the stock and expressed awareness of investor dissatisfaction with current valuations.
• Regulatory Risks: The reliance on FDA approval processes introduces uncertainty, particularly with the new Project Optimus requirements that may necessitate additional trials or data.

5. Notable Q&A Insights

• Dosage Optimization: In response to questions about dosage levels, management emphasized that they are monitoring drug exposure in patients to optimize dosing regimens for safety and efficacy.
• Target Populations: The next-generation capecitabine will initially target patients typically prescribed capecitabine, with expectations of expanding to a broader population.
• Clinical Trial Costs: Future trial costs are uncertain and will depend on FDA discussions regarding study design and requirements.
• Biomarker Development: The company is working on a macro molecule assay for potential biomarkers, with plans to submit a protocol for a Phase 2b trial by the end of the year.

Overall, while Processa Pharmaceuticals is making strategic shifts to focus on oncology and enhance its drug development processes, it faces significant financial losses and regulatory challenges that could impact its future performance.